New York, August 28, 2014 -- Moody's Investors Service commented that the acquisition of Gallus BioPharmaceuticals, LLC (Gallus, unrated), a contract manufacturing company specializing in biologics by JLL/Delta Dutch NewCo (also known as DPx Holdings, formerly known as Patheon) for an undisclosed amount, is credit negative. Gallus, with its two facilities in St. Louis, MO and Princeton, NJ, is a mammalian cell culture contract development and manufacturing organization (CMO) for the pharmaceutical and biotechnology industry. However, there is no immediate impact on DPx's B3 Corporate Family Rating or other long term ratings, or the stable rating outlook.

Vollständigen Artikel bei Moodys lesen